ELI LILLY AND COMPANY (LLY)

Eli Lilly and Company operates in the Pharmaceutical Preparations industry (SIC 2834). The company is a global pharmaceutical manufacturer focused on discovering, developing, and commercializing medicines for diabetes, obesity, oncology, immunology, neuroscience, and other serious health conditions. Its leading products include Mounjaro and Zepbound, which use tirzepatide to treat type 2 diabetes and obesity, respectively, as well as Verzenio for breast cancer and Kisunla for early symptomatic Alzheimer's disease. Lilly is expanding its portfolio through research in metabolic health, next-generation weight-loss treatments, genetic medicine, and AI-enabled drug discovery. Incorporated in IN. Headquartered in Indianapolis, IN. Fiscal year ends December 31. Filing category: Large accelerated filer.

TickerLLY
CompanyELI LILLY AND COMPANY
ExchangeNYSE
HeadquartersINDIANAPOLIS, IN

Income statement — period ending 2026-06-30

Comprehensive Income (Loss), Net of Tax, Attributable to Parent$7,167,000,000
Cost of Goods and Services Sold$3,268,000,000
Earnings Per Share, Basic8 USD/shares
Earnings Per Share, Diluted8 USD/shares
Gross Profit (derived)$19,706,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest$9,247,000,000
Income Tax Expense (Benefit)$2,152,000,000
Net Income (Loss) Attributable to Parent$7,095,000,000
Nonoperating Income (Expense)$269,000,000
Revenues$22,974,000,000
Selling, General and Administrative Expense$3,430,000,000
Share-based Payment Arrangement, Noncash Expense$362,000,000
Weighted Average Number of Shares Outstanding, Diluted893,700,000 shares
Weighted Average Number of Shares Outstanding, Basic892,400,000 shares

Sourced from SEC EDGAR/XBRL filings via StockSpectro.

View full interactive research on StockSpectro